Kimball (KE) Q2 2026 Earnings Call Transcript

Kimball Electronics reported Q2 net sales of $341.3 million, down 5%, but gross margin improved 160 bps to 8.2% and adjusted operating income rose to $15.3 million from $13.3 million. Medical revenue grew 15% to $96 million and the company raised FY2026 sales guidance to $1.40 billion-$1.46 billion, while maintaining capex at $50 million-$60 million. Headwinds remain in North American Automotive and Industrial, and the new Indianapolis medical facility will pressure margins in the near term before supporting longer-term growth.

Analysis

The market is likely to underappreciate how much of this quarter is a transition story rather than a demand story. The near-term earnings quality improves because fixed-cost absorption, restructuring, and FX are masking underlying volume pressure, but the new Indianapolis medical footprint creates a 2-3 quarter earnings air pocket before it becomes an asset. That means the stock can work on guidance and mix alone, but the operating leverage inflection is probably deferred until the back half of FY26 or into FY27.

The bigger second-order effect is that Medical is becoming the company’s valuation anchor while Automotive becomes the cash flow stabilizer. If Medical keeps comping up and the new facility starts winning lift-and-shift programs, the multiple should migrate toward medical-device outsourcing peers rather than cyclical EMS names; however, customer concentration and ramp risk mean the re-rate is not linear. The most likely path is multiple expansion only after the market sees a clean quarter where Indy no longer depresses margins and working capital normalizes.

Auto looks less broken than the headline suggests. The legacy braking program anniversary removes an obvious drag, and Europe is emerging as the offset to North America, but the real option value is in higher-content assemblies like EPP and second-steering designs; those are smaller today but can extend content per vehicle and partially de-risk platform churn. Industrial remains the weak link because it is the least likely to benefit from the same portfolio re-rating, and that creates a hidden portfolio-rotation opportunity: capital is being pulled toward faster-growth medical while the industrial segment likely gets less strategic attention and slower recovery.

The contrarian setup is that the stock may already be pricing the good news from margin expansion and raised guidance, while underpricing the duration of near-term dilution from dual-running facilities and elevated S&A. If management executes on cash conversion and keeps debt trending down, downside should be buffered; if not, the market will punish the combination of low absolute margins and high customer concentration. The key catalyst is not this quarter’s EPS, but proof that the new capacity converts into signed programs rather than just a longer funnel.

Key Decisions for Investors

• Long KE for 3-6 months on a pullback toward post-earnings weakness: reward is a rerate toward medical-outsourcing comps if Indy ramps cleanly; risk is 8-12% downside if the market focuses on near-term margin drag and customer concentration.
• Sell KE cash-secured puts 1-2 quarters out if implied volatility spikes after the call: monetizes the stock’s transition period while waiting for visibility on the Indy ramp; downside is manageable if you are willing to own into FY26 execution.
• Pair trade: long KE / short a lower-quality cyclical EMS peer over 6-12 months: KE has clearer mix improvement and a self-funded growth story, while the short should lag if end-market softness persists.
• For event-driven accounts, buy KE Jan/Apr call spreads only after confirmation of first Indy customer wins: upside is strongest if the market re-prices the facility as incremental revenue rather than pure cost drag; avoid paying for upside before program conversion is visible.
• If seeking a hedged industrial exposure, avoid using KE as a proxy for macro recovery until Industrial shows at least one clean quarter of sequential stabilization; the portfolio is still too dependent on Medical momentum to call the turnaround complete.